BRAIN Biotech AG Shareholders Approve All Agenda Items at 2026 Annual General Meeting

At the 2026 Annual General Meeting of BRAIN Biotech AG, shareholders approved all agenda items with a broad majority, with 61.82% of share capital represented at the time of voting. Dr. Ursula La Cognata of Berlin, managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board for a four-year term. She had previously been appointed by the Darmstadt Local Court as a new member effective July 11, 2025, until the next Annual General Meeting. The detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2026/.

Supervisory Board Chairman Dr. Michael Majerus expressed confidence in the company's development opportunities during his statement to shareholders. He highlighted BRAIN Biotech AG's successful product business, strong market position in contract research, expected revenues from monetization initiatives and pharmaceutical project licensing, and further product innovations from the BRAINBioIncubator segment. This endorsement from leadership reinforces the strategic direction approved by shareholders at the meeting.

CEO Adriaan Moelker addressed the company's strategy in his speech, stating that the two-pillar approach with the product-oriented BRAINBiocatalysts segment and the research-intensive BRAINBioIncubator segment remains the right strategy. This approach enables the company to monetize investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business. Moelker emphasized that the company's relatively small size allows for quick and flexible responses to customer needs with short communication channels, offering innovative biotechnological solutions that represent unique selling points. He stressed the importance of maintaining this advantage even during future growth periods.

Moelker also provided updates on operational developments, reporting on the consolidation of production and sales for enzymes and food ingredients for the baking and beverage industries at a new location in the Netherlands. The new building, which will house a modern baking application center, laboratory, and production areas, is nearing completion. This expansion supports the company's position as a leader in researching, developing, and producing specialty enzymes with a focus on the food and life sciences industries. The company also develops microbial production strains and scalable bioprocesses for economic production of specialty enzymes and other proteins while offering customized biological solutions for more sustainable products and efficient processes.

The shareholder approval of all agenda items, including the supervisory board election, demonstrates investor confidence in the company's leadership and strategic direction. The management's emphasis on maintaining agile operations despite growth ambitions suggests a balanced approach to scaling while preserving competitive advantages. The operational updates regarding the Netherlands facility indicate ongoing investment in infrastructure to support business segments. For more information about the company, visit: http://www.brain-biotech-group.com.